JOURNAL HEBDO RIVE NORDBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL HEBDO RIVE NORD
Company Title:
Company Description:
Keywords to Search:
Company Address:	1004 Rue Notre-Dame,REPENTIGNY,QC,Canada
ZIP Code: Postal Code:	J5Y1S9
Telephone Number:	4505815120
Fax Number:	4505816509
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	2711-01
USA SIC Description:	Newspapers (Publishers)
Number of Employees:	20 to 49
Sales Amount:	$5 to 10 million
Credit History: Credit Report:	Excellent
Contact Person:	Jacques Boulanger
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
JULIE TREMBLAY DESIGN ENR
JOURNAL LARTISAN
JOURNAL LARTISAN

Next company profile:
JOTANAU INC
JOLY, PIERRE
JOLY & ZALOUM

Company News:

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day
First-Line Camizestrant for Emerging ESR1-Mutated Advanced Breast . . .
Mutations in ESR1 are the most common mechanism of acquired resistance to treatment with an aromatase inhibitor plus a cyclin-dependent kinase 4 and 6 (CDK4 6) inhibitor for advanced breast cancer
Overall Survival with Inavolisib in PIK3CA-Mutated Advanced Breast . . .
In the phase 3, double-blind, randomized INAVO120 trial, treatment with inavolisib plus palbociclib–fulvestrant led to a significant progression-free survival benefit, as compared with placebo
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP
Lorundrostat Efficacy and Safety in Patients with Uncontrolled . . .
Background Aldosterone dysregulation contributes to hypertension Lorundrostat is an aldosterone synthase inhibitor, but data on its efficacy and safety in patients with hypertension are limited
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung . . .
Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC) Zongertinib is an oral